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Introduction: Identification of adenocarcinoma (AC) and squa-
mous cell carcinoma (SCC) histology of non–small-cell lung cancer 
(NSCLC) in biopsies is clinically important but can be inaccurate by 
routine histopathologic examination. We quantify this inaccuracy at a 
cancer center, and evaluate the utility of a microRNA-based method 
to histotype AC/SCC in biopsies.
Methods: RNA was extracted from tissue sections with greater than 
90% tumor content that were macro- or micro-dissected from for-
malin-fixed, paraffin-embedded biopsy specimens. MicroRNAs in 
RNA from the biopsies and from resected tumors were quantified by 
TaqMan reverse transcription-polymerase chain reaction assays and 
normalized against the RNU6B housekeeping RNA. Publicly avail-
able microRNA expression datasets were examined.
Results: NSCLC subtyping of small biopsy specimens by routine 
histopathologic examination either failed or mistyped the histology 
of 21% of 190 cases. Using 77 resectates, an reverse transcription-
polymerase chain reaction-based assay of microRNAs miR-21, miR-
205, and miR-375 was developed to identify AC and SCC subtypes of 
NSCLC. This method identified the AC/SCC histotypes of 25 biop-
sies with an accuracy of 96%, and correctly histotyped all 12 cases 
for which the histology had been mistyped by routine histopathologic 
examination of the biopsy. Examination of publicly available datasets 
identified miR-205 and miR-375 as microRNAs with the best ability 
to histotype AC and SCC, and that levels of the two microRNAs in 
AC or SCC are unaffected by the pathologic stage of the tumor or the 
age or race of the patient.
Conclusions: Histotypic microRNA assays can aid the subtyping of 
NSCLC biopsies as AC or SCC by standard histopathologic methods.
Key Words: Non–small-cell lung cancer, MicroRNA, Biopsy.
(J Thorac Oncol. 2015;10: 446–453)
Subtyping of non–small-cell lung cancer (NSCLC) to identify adenocarcinoma (AC) and squamous cell carci-
noma (SCC) histotypes which constitute approximately 85% 
of NSCLC is clinically important. AC is more susceptible 
to the antifolate drug pemetrexed, whereas the SCC subtype 
is largely unresponsive to it1, and SCC but not AC patients 
treated with the anti-angiogenic agent bevacizumab are signif-
icantly likely to suffer pulmonary hemorrhage.2 Identification 
of the correct histology also prompts the appropriate evalua-
tion of the tumor for genetic changes that predict response to 
targeted agents; e.g., for EGFR mutations and ALK gene rear-
rangement in case of AC but not SCC, and for FGFR1 gene 
amplification and DDR2 mutation in SCC but not AC3.
Examination of morphology and protein expression 
is the standard histopathologic method to identify AC and 
SCC subtypes in small biopsy specimens. Although it can 
be highly accurate with the right protein markers and exper-
tise,4–8 AC/SCC subtyping by histopathologic examination of 
biopsy material in routine clinical settings can be incorrect for 
15%–35% cases.9–13 A number of studies have demonstrated 
the histotyping utility of microRNAs for NSCLC,14–21 a class 
of approximately 2500 ultra-short, noncoding cellular RNAs 
that are also remarkably preserved after formalin fixation of 
biospecimens.22–24 In particular, a reverse transcription-poly-
merase chain reaction (RT-PCR)-based assay of microRNAs 
miR-205 and miR-21, and the RNU6-2 (U6B) small nucleolar 
RNA developed by Lebanony et al.14 has been successfully 
used by other groups to identify AC and SCC subtypes of 
resected specimens with accuracy rates of 90%–100%.21,25,26 
This method had an accuracy rate of 95% with biopsy material 
in the one study in which this was examined.27
In this study, we note the inaccuracy of routine histo-
pathologic examination at a cancer hospital for subtyping 
NSCLC in biopsies by examining the discordance of the his-
tological diagnoses with those made for the resected tumor 
specimens. We evaluate the performance of the microRNA 
assay of Lebanony et al. for AC/SCC histotyping of resected 
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tumors. By analyzing publicly available data on microRNA 
expression in NSCLC tumors, we identify miR-375 as a his-
totypic microRNA whose measurement can be used to impro-
vise the performance of the Lebanony assay, and we test this 
improved method with biopsied tumor tissue.
MATERIALS AND METHODS
Statement on Ethics
This study was conducted in accordance with the 
amended Declaration of Helsinki under protocols I129008 
and NHR015110 of the Institutional Review Board of Roswell 
Park Cancer Institute (RPCI).
Analyses of External Lung SCC and AC 
MicroRNA Expression Datasets
Four studies28–31 were identified to have publicly avail-
able, high-throughput expression data for greater than or 
equal to 24 each of SCC and AC cases for microRNAs, includ-
ing miR-21 and miR-205 that are assessed in the Lebanony 
method14 for AC/SCC subtyping. This identification, and the 
analyses of microRNA expression data from these studies 
is described in Appendix 1 and Table S1 in Supplementary 
Digital Content, http://links.lww.com/JTO/A750. Clinical 
and microRNA expression data generated on Genome 
Analyzer or HiSeq RNA sequencing platforms (Illumina, 
San Diego, CA) for AC/SCC cases of the Cancer Genome 
Atlas (TCGA) project were obtained from the Broad Institute 
Firehose (data standardization run of February 22, 2013). The 
edgeR Bioconductor package32 was used in R to normalize 
microRNA count data for analyzing differential expression 
with Fisher’s exact test. Characteristics of the TCGA patient 
cohorts, and processing and analyses of the data are described 
in Appendix 2, and Tables S2 and S3 in Supplementary Digital 
Content, http://links.lww.com/JTO/A750.
Identification of Cohort to Evaluate 
the Accuracy of Subtyping NSCLC by 
Histopathologic Examination of Biopsies
The tumor registry of RPCI was queried to identify 
190 cases of primary NSCLC of lung parenchyma that were 
treated by resective surgery at RPCI during 2008–2010, and 
for whom histopathologic examinations had been performed 
for both presurgery biopsy and surgical resectate tissue speci-
mens, with a diagnosis of NSCLC obtained with the latter. 
Relevant characteristics of this cohort are noted in Table S4 
in Supplementary Digital Content, http://links.lww.com/JTO/
A750. All resectate specimens were histopathologically exam-
ined at RPCI. For about two-thirds of the cases, biopsies had 
been performed outside RPCI, reflecting the stature of RPCI 
as a tertiary referral center. When multiple biopsies had been 
performed for a case, only the result of the biopsy used for final 
diagnosis was considered. Slides of biopsy specimens were 
re-examined at RPCI if histopathologic examination of biopsy 
specimens had been conducted elsewhere, and RPCI’s evalua-
tion of histology was considered for analysis, but for the rare 
cases for which slides of biopsy specimens were unavailable, 
the nonRPCI pathologists’ evaluations of histology were used. 
Histology of a resectate, determined from tissue morphology, 
and immunohistochemical examinations in some cases, was 
taken as the true NSCLC histology when evaluating the accu-
racy of histology determined for the biopsy specimens.
Resectate and Biopsy Specimens
Paraffin-embedded formalin-fixed specimens for primary 
AC/SCC tumor biopsies (n = 25) or resectates (n = 77), and clin-
ical data were obtained from RPCI’s Pathology Research and 
Clinical Data Networks. Relevant characteristics for the speci-
mens are noted in Tables S5 and S6 in Supplementary Digital 
Content, http://links.lww.com/JTO/A750. The 6th American 
Joint Committee on Cancer tumor staging system was used.
Tissue Microdissection and RNA Extraction
Areas with greater than 90% cellular tumor content in 
hematoxylin-eosin-stained 8-μm-thick sections of biopsies 
were microdissected by laser under a pathologist’s supervi-
sion on an LMD6000 system (Leica, Wetzlar, Germany) as 
described previously.33 Dissected areas averaged 25.6 mm2 
(range = 0.9–98.4; standard deviation [SD] = 26.9). Six 
biopsy specimens with large contiguous areas of tumor were 
dissected with a scalpel under naked eye. RNA extracted from 
the dissectates with the FFPE RNA Purification kit (Norgen 
Biotek, Thorold, Canada) averaged 0.78 μg (range = 0.03–
3.76, SD = 0.97) when quantified using RiboGreen.33 RNA 
extraction from resectates with greater than 70% tumor con-
tent using RecoverAll (n = 56; Ambion, Austin, TX) or High 
Pure miRNA (n = 21; Roche, Indianapolis, IN) has been 
described.29,34
MicroRNA RT-PCR Assays
RNA samples were at -80°C for a few days to 5 years 
when assayed (detailed in Tables S5, and S6 in Supplementary 
Digital Content, http://links.lww.com/JTO/A750). TaqMan 
MicroRNA assays35 (Applied Biosystems, Foster City, CA) 
000397, 000509, 000564, and 001093 were, respectively, used 
to quantify miR-21-5p, miR-205-5p, miR-375-3p, and RNU6-
2 (U6B), a nucleolar housekeeping small RNA, as quantifica-
tion cycle (C
q
) values, which are inversely and logarithmically 
proportional to analyte concentrations. MiR-21-5p, miR-
205-5p, and RNU6-2 are the three RNAs that are analyzed in 
the AC–SCC typing method described by Lebanony et al.14
Typically, a tissue RNA sample was simultaneously 
assayed by RT-PCR for miR-21, miR-205 and miR-375 in 
the same experiment, and U6B was quantified any time that 
a microRNA was, with RT reactions performed in one batch 
and all PCR reactions for an RT batch set up on one 384-well 
plate. RT batches always included a negative, no RNA con-
trol (water), and RT-PCR experiments were repeated if a C
q
 
value was detected and lesser than 36 for the negative control. 
RT-PCR experiments that used tissue RNA also included 1–2 
standard RNA samples, in duplicate, for each of the microR-
NAs, and U6B, that were being quantified in the experiments. 
The standard samples were dilutions in water of synthetic, 5′ 
phosphorylated small RNA standards with sequences of the 
human U6B or mature microRNAs (Life Technologies) such 
that an RT reaction had 102–7 molecules of a standard.
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For calculation of molarity values from the raw C
q
 value 
for a microRNA or U6B for a tissue RNA sample, the C
q
 value 
was first adjusted using a calibration factor, and then used in 
a linear equation derived from C
q
 values obtained with the 
synthetic RNA standard at different molarities (Fig. S1 in 
Supplementary Digital Content, http://links.lww.com/JTO/
A750). The calibration factor was the average deviation of 
the C
q
 values seen for an experiment’s standard controls of a 
certain molarity from the C
q
 values expected for that molar-
ity from the standard curves. Values of calibration factors are 
listed in Table S7 in Supplementary Digital Content, http://
links.lww.com/JTO/A750. Calibration of the raw C
q
 values for 
molarity determinations also resulted in inter-experiment cali-
bration of the C
q
 values. XΔC
q
Y, measurement of microRNA 
X relative to that of Y, was calculated by subtracting C
q
 for Y 
from that for X. The Lebanony score14 was calculated as miR-
205 ΔC
q
U6B - (miR-21 ΔC
q
U6B)/2. C
q
 values and calculations 
are in Tables S7 and S8 in Supplementary Digital Content, 
http://links.lww.com/JTO/A750.
Other
Unless noted otherwise, Prism software (version 6.0b; 
GraphPad, La Jolla, CA) was used for data-plotting and statis-
tical analyses, a p value less than 0.05 was associated with sta-
tistical significance, and groups were compared for categorical 
and quantitative variables, respectively, using χ2 and standard 
two-tailed t tests. Areas under receiver operating characteristic 
(ROC) curves (AUCs) were compared as per DeLong et al.36 
using the StAR online tool.37
RESULTS
Inaccurate Histotyping of NSCLC Biopsies
Among all primary NSCLC cases that were treated 
during 2008–2010 by surgical resection at RPCI, a tertiary 
referral cancer center, histological subtyping of the can-
cer by routine pathologic examination of both biopsied and 
resected tumor tissue specimens was done for 190 (charac-
teristics of the cases are noted in Table S4 in Supplementary 
Digital Content, http://links.lww.com/JTO/A750). Although 
NSCLC was identified in 184 of the 190 biopsies, its sub-
type was unidentifiable for 24 (13.0%), and discordant from 
the subtype diagnosed for the resectate for 15 (9.4%) of the 
remaining 160 (Table 1). The discordance or inaccuracy rate 
was higher for cases that had neoadjuvant chemotherapy 
with or without radiation (33% versus 17%; p = 0.02), or for 
which the biopsy method was fine needle aspiration instead of 
core biopsy (30% versus 16%; p = 0.02), but was unaffected 
if cases had sole radiation therapy, bronchoscopy instead of 
computer tomography for biopsy, or biopsy was performed 
outside RPCI. Among the 101 AC cases, the AC histotype was 
missed in biopsy examination of 22 cases (21.8%), with four 
(18%) of them mistyped as SCC. Mistyping of SCC as AC 
was 50% among 12 cases (17%) whose SCC histotype was 
missed in biopsy examination.
Identification of miR-375 as a MicroRNA 
that May Improve the Performance of the 
Lebanony Method for AC/SCC Subtyping
The Lebanony method is based on the relatively higher 
expression of miR-205 in SCC compared with AC to distin-
guish these subtypes of lung cancer. When the study described 
here was initiated, four studies28–31 with publicly available, 
high-throughput microRNA expression datasets for greater 
than or equal to 24 each of lung AC and SCC tumors had been 
published (Appendix 1 in Supplementary Digital Content, 
http://links.lww.com/JTO/A750). ROC analyses of these data-
sets for association of microRNA levels with AC/SCC histol-
ogy showed that, besides miR-205, microRNA miR-375 had 
the best AUC values among all microRNAs, with miR-375 
levels being higher in AC compared with SCC (Table S1 in 
Supplementary Digital Content, http://links.lww.com/JTO/
A750). This suggests that measurement of miR-375 may be 
useful for improving the accuracy of the Lebanony method for 
AC/SCC subtyping.
To check for microRNAs that may have a better AC/SCC 
histotyping ability than miR-205 and miR-375, tumor microRNA 
expression data from the Cancer Genome Atlas project for all 
334 primary lung AC and 300 primary lung SCC cases of the 
project for which data was available was analyzed for differential 
expression and ROC (Appendix 2 and Table S2 in Supplementary 
Digital Content, http://links.lww.com/JTO/A750). Expression 
of 214 and 216 microRNAs in SCC was, respectively, signifi-
cantly higher and lower in SCC compared with AC. Average 
TABLE 1.  Histology Determined by Pathologic Examination of Biopsies of 190 Cases of Resected Non–Small-Cell Lung Cancera
Biopsy Histology
Resectate Histology
Adenocarcinoma 
(101)
Adenosquamous 
Carcinoma (3)
Large-Cell 
Carcinoma (1)
Neuroendocrine 
Tumor (9)
Squamous Cell 
Carcinoma (69)
Unspecified 
Malignant  
Tumor (1)
Unspecified 
Non–Small-Cell 
Carcinoma (6)
Adenocarcinoma (86) 79 6 1
Neuroendocrine tumor (9) 9
Small cell carcinoma (2) 1 1
Squamous cell carcinoma (65) 4 3 57 1
Unspecified malignant tumor (4) 3 1
Unspecified non–small-cell 
carcinoma (24)
15 1 5 3
aSums along columns and rows are noted in parentheses
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fold-change and ROC AUC values were, respectively, ≥ 2 and ≥ 
0.8 for 12 of the 430 differentially expressed microRNAs (Table 
S3 in Supplementary Digital Content, http://links.lww.com/JTO/
A750). These 12 microRNAs, thus deemed to have significant 
histotyping potential, included miR-205 and miR-375 whose 
AUC values 0.96 and 0.88, respectively, were highest among 
the subsets of upregulated and downregulated microRNAs. 
MiR-205 or miR-375 levels in either AC or SCC tumors did not 
significantly vary by tumor stage (pathologic stage I/II versus 
III/IV), or patient age (below versus above group mean) or race 
(Caucasian versus other). The TCGA data was also examined for 
expression of the histotypic microRNAs in tumor-adjacent nor-
mal lung tissue (Fig. 1) because biopsy specimens contain nor-
mal tissue to a varying degree and expression of a microRNA in 
normal lung has to be considered when evaluating the microR-
NA’s histotypic utility. Although miR-375 is overexpressed in 
AC, its expression was noted as unchanged in SCC compared 
with normal tissue (p = 0.79), and miR-205 expression, higher 
in SCC, was unchanged in AC compared with normal tissue 
(p = 0.08; Fig. 1). These observations from the largest AC/SCC 
microRNA expression dataset therefore support the use of miR-
205 and miR-375 for AC/SCC subtyping.
MicroRNA Assays of Resected Tumors
To test the Lebanony14 method for AC/SCC subtyp-
ing, TaqMan RT-PCR was used to quantify miR-21, miR-205, 
and U6B in 5 ng RNA of 49 AC and 28 SCC stage I tumor 
resectates (characteristics of the cases are noted in Table S5 
in Supplementary Digital Content, http://links.lww.com/JTO/
A750). MicroRNA miR-375 was also quantified because, as 
noted earlier, it had the highest AUC value besides miR-205 in 
ROC analyses of microRNA levels and AC/SCC histology, and 
we wished to test the performance of an independent miR-375 
assay to histotype AC and SCC as well as check if miR-375 
assessment could improve the performance of the Lebanony 
method. Two RNA samples were assayed in 2–5 different 
experiments to assess replicability of the RT-PCR assays.
MiR-21, miR-205, and miR-375 in 53 of the 77 resectate 
RNA samples had previously been measured using Affymetrix 
GeneChip miRNA oligonucleotide microarrays.34 Comparison 
of the microRNA quantifications obtained by the RT-PCR and 
microarray methods revealed Pearson correlation coefficient 
values of 0.76–0.94 and indicated validity of the RT-PCR 
assays (Fig. S1 in Supplementary Digital Content, http://links.
lww.com/JTO/A750). Coefficients of variation for raw C
q
 val-
ues of the microRNAs were 0.002–0.006. Coefficients of vari-
ation for microRNA C
q
 values normalized to U6B (ΔC
q
U6B) 
were 0.064–0.088, and was 0.037 for miR-205 ΔC
q
U6B - (miR-
21 ΔC
q
U6B)/2, the Lebanony score. Use of 25-fold less RNA 
(0.2 ng) in the assays did not significantly affect the Lebanony 
score or the miR-205 ΔC
q
U6B value (Pearson correlation coef-
ficients greater than or equal to 0.95); coefficients for raw C
q
 
values were 0.74–0.98 (Fig. 2).
The average Lebanony score of the 28 SCC cases was 
-1.0 (range = -4.1 to 5.7; SD = 2.6) compared with 5.2 for the 49 
AC cases (-2.2 to 13.2; 3.1), indicating an approximately 26-fold 
higher miR-205 expression in SCC (Fig. 3A). In ROC analysis, 
the scores had an AUC of 0.93 (Fig. 3B). With the suggested cut-
off value of 2.5 to classify AC and SCC, the Lebanony14 method 
was found to have an accuracy of 83% (64 of 77), with misclassi-
fication seen for 9 (18%) and 4 (14%) of the AC and SCC cases, 
respectively. Because synthetic microRNA standards were used 
in the RT-PCR assays, the molar equivalents of the Lebanony 
scores could be determined (Fig. S2 in Supplementary Digital 
Content, http://links.lww.com/JTO/A750, and Fig. 3C) and the 
cut-off value of 2.5 was calculated to be 10-2.3 (one molecule of 
miR-205 per 194 of U6B and miR-21).
ROC analyses of publicly available microRNA expres-
sion data obtained in the four identifiable published studies for 
greater than or equal to 24 each of lung AC and SCC tumors 
(Appendix 1 in Supplementary Digital Content, http://links.
lww.com/JTO/A750) suggested that the histotypic value of 
miR-205 was not affected by disregarding miR-21 measure-
ments (Fig. S3 in Supplementary Digital Content, http://links.
lww.com/JTO/A750). If indeed miR-205 relative to just U6B, 
instead of both U6B and miR-21, could be used for histotyping 
the resectates was therefore tested by examining the RT-PCR 
data. The average miR-205 ΔC
q
U6B value of -3.4 for SCC 
(range = -8.1 to 2.2; SD = 2.8) was significantly lower than the 
value of 2.4 for AC (-4.2 to 10.5; 3.1; Fig. 3A). The miR-205 
ΔC
q
U6B equivalent of the Lebanony score cut-off value of 2.5 
was identified by linear regression analysis as -0.17 (Fig. S4 
in Supplementary Digital Content, http://links.lww.com/JTO/
A750), 10-2.4 in molar terms (one molecule of miR-205 per 272 
U6B; Fig. 3C). Using the cut-off of -0.17, miR-205 ΔC
q
U6B val-
ues could be used to identify AC/SCC subtypes with an accu-
racy of 82% (63 of 77), with misclassification seen for 9 (18%) 
and 5 (17%) of the AC and SCC cases, respectively. The AUC 
for miR-205 ΔC
q
U6B values was 0.91, not significantly different 
from that for Lebanony scores (p = 0.07; Fig. 3B).
FIGURE 1.  Histotypic microRNAs to distinguish lung 
SCC and AC identified in analyses of data from the Cancer 
Genome Atlas. Count per million microRNAs in primary AC 
(n = 334, black) and SCC (n = 300, gray) tumor or tumor-
adjacent normal lung tissues (n = 79, white) for 10 of the 12 
microRNAs identified in the analyses are depicted as mean 
and 95% confidence interval values. SCC, squamous cell 
carcinoma; AC, adenocarcinoma.
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Although miR-375 expression was higher in AC than 
SCC, AUCs in ROC analyses of miR-375 ΔC
q
U6B or ΔC
q
miR-205, 
respectively, were 0.72 and 0.90 (Fig. S5 in Supplementary 
Digital Content, http://links.lww.com/JTO/A750), less than 
those seen for the Lebanony score or miR-205 ΔC
q
U6B values. 
However, miR-375 ΔC
q
U6B values appeared to have the potential 
to reduce misclassification of AC with a less than 2.5 Lebanony 
score as SCC by the Lebanony method (Fig. 4). The median 
of miR-375 ΔC
q
U6B and SD of Lebanony score values for the 
AC cases with Lebanony score greater than 2.5 were -1.25 and 
2.44, respectively, and we modified the Lebanony classifica-
tion system to classify a case with Lebanony score between 2.5 
and 2.5–2.44 (0.06; 10-1.5 in molar terms) as AC instead of SCC 
if its miR-375 ΔC
q
U6B value was below -1.25 (10-4.2 in molar 
terms). This improved the AC/SCC subtyping accuracy of the 
Lebanony method from 83% (64 of 77) to 92% (71 of 77) by 
reducing AC misclassification from 18% (9 of 49) to 4% (2 of 
49) (Fig. 4). The improvement in accuracy from 83% to 92% 
was statistically significant (McNemar’s test p = 0.023).
Histotyping Biopsies by MicroRNA Measurements
Having evaluated and refined the Lebanony method using 
resected AC/SCC tumors, the modified method was tested 
against biopsy specimens of tumors later resected and identi-
fied as AC (n = 8) or SCC (n = 17). Macro- or laser-assisted 
FIGURE 2.  Correlation between small RNA quantifica-
tions obtained by RT-PCR using two amounts of tissue RNA. 
Measurements obtained using 0.2 ng RNA of 14 resected 
lung cancers of U6B and miR-21, miR-205, and miR-375 as 
quantification cycle (Cq) values, and of miR-205 relative to 
U6B and miR-21 (Lebanony score), or only U6B (miR-205 
ΔCq
U6B) are plotted against those obtained with 5 ng RNA. 
The Pearson correlation coefficient (r) with 95% confidence 
interval, and the linear regression line generated with the 
least squares fitting technique are also shown. RT-PCR, 
reverse transcription-polymerase chain reaction.
FIGURE 3.  Expression of miR-205 in lung SCC and AC resec-
tates. RT-PCR was used to quantify miR-205 relative to U6B 
and miR-21 (Lebanony score), or only U6B (miR-205 ∆Cq
U6B) in 
5 ng RNA for 49 AC and 28 SCC cases. For each type of mea-
surement, A shows dot-plots of individual values along with 
histology-specific group means and standard deviations; B 
shows receiver operating characteristic curves, along the AUC 
with 95% confidence interval, for the miR-205 measurements 
to discriminate SCC from AC; and, C shows the measure-
ment values in terms of molarity along with linear regression 
lines and their slopes (m) and Y intercepts (b) determined 
by the least squares fitting technique. Molarity equivalent of 
the Lebanony score could be determined for only 56 of the 
total 77 cases. SCC, squamous cell carcinoma; AC, adeno-
carcinoma; RT-PCR, reverse transcription-polymerase chain 
reaction; AUC, area under curve.
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microdissection was used to isolate specimen sections with 
greater than 90% tumor content. Histopathologic examination 
of the biopsies had failed at identifying or misidentified the 
NSCLC subtype for 12 of the cases (48%) (Table 2). The modi-
fied Lebanony method using 0.75 ng RNA input, on the other 
hand, correctly identified the AC/SCC subtype of NSCLC in 
biopsy tissue for 24 (96%) of the 25 cases; the accuracy with 
the original Lebanony method was 88% (Table 2). Unlike for 
the set of 77 resectate samples (Fig. 4), the improvement in 
accuracy of the biopsy histotyping with the modified Lebanony 
method from 88% to 96% was not statistically significant 
(McNemar’s test p = 0.48), although this may have been due to 
the small sample size of 25. The single case that was mistyped, 
an SCC, was the only one of this study with an undetectable 
miR-205 C
q
 in RT-PCR assays and this may be because of a 
variation in sequence of miR-205 in the individual.
DISCUSSION
Our study finds that histological subtyping of NSCLC 
in small biopsy specimens by routine histopathologic exami-
nation either fails or mistypes the histology for 21% of cases 
(Table 1), a rate similar to that noted in other studies.9–13 Such 
inaccuracy probably arises from scarcity of tumor content, tis-
sue heterogeneity, and loss of tissue architecture that are often 
seen in small biopsy material. Recent studies have suggested 
that appropriate immunohistochemical assays can be used to 
histotype AC and SCC in small biopsy samples with very high 
accuracy (93%–96%).4,6,8 Studies with resected tumor speci-
mens have shown that immunohistochemistry can be used 
with 100% accuracy to identify AC or SCC tumors.5 Highly 
specific protein markers, such as CD141 (thrombomodulin), 
desmocollin 3 and Sox2 for SCC,38,39 and napsin A for AC8,40,41 
have been identified, and the accuracy of AC–SCC histotyping 
by immunohistochemistry in routine pathologic examinations 
will improve through the use of such markers and optimal 
algorithms.
Although immunohistochemical markers for AC/SCC 
that are more accurate than the ones used for the histological 
diagnoses of samples of our study are known,4–8 the findings 
presented here show that histotypic microRNAs can be used to 
aid AC/SCC subtyping of NSCLC. Lebanony et al.’s method 
that measures miR-21, miR-205, and U6B to histotype AC and 
SCC has been successfully used with 90%–100% accuracy 
with resectates in at least three studies and with biopsies in 
one.21,25,26 The accuracy of the method with resectates in this 
study was 83%, less than that reported in the previous studies. 
Thus, as pointed out by the authors of one of these studies,25 
the Lebanony method misclassifies a significant percentage of 
cases. However, the accuracy of the Lebanony method could 
be significantly increased to 92% by incorporating miR-375 
in the method (Fig. 4). The modified method had an accu-
racy of 96% against dissected small biopsy specimens with 
greater than 90% tumor content; 48% of the biopsies had been 
mistyped in routine histopathologic examination (Table 2). 
These findings suggest that histotypic microRNA assays can 
aid the subtyping of NSCLC biopsies as AC or SCC by stan-
dard histopathologic methods. In our experience, a specimen 
that is not formalin-fixed can be evaluated for microRNA 
expression by RT-PCR within 5–6 hours, including the time 
taken for RNA extraction; formalin-fixed specimens require 
an additional, overnight proteinase digestion step. Results of 
microRNA RT-PCR assays are quantitative, and multiple sam-
ples can be subjected to PCR in one batch. Reagents for RNA 
extraction and RT-PCR assays are inexpensive and readily 
available from commercial sources. Thus, microRNA assays 
to histotype AC/SCC can be easily performed in a pathology 
laboratory equipped with a quantitative PCR equipment, with 
effort, time and material costs similar to those for immunohis-
tochemical assays.
The utility of miR-375 for AC/SCC subtyping has also 
been noted in a recent study15 and seems to have a biologi-
cal basis. Differentiation of alveolar epithelial cells (AEC) 
from a nonsquamous, AEC II phenotype to a squamous AEC 
I phenotype is accompanied by a decreasing level of miR-
375, and artificial overexpression of miR-375 decreases the 
propensity of cells to undergo squamous differentiation.42 
Analyses of publicly available microRNA expression data, 
including that for more than 600 AC/SCC cases of the TCGA 
project, shows that miR-205 and miR-375 are likely to be the 
best microRNA markers to histotype AC and SCC (Tables 
S1 and S3 in Supplementary Digital Content, http://links.
lww.com/JTO/A750). Levels of these two microRNAs in 
tumor tissues do not seem to be affected by tumor stage or 
patient age or race.
Our study suggests that the modified Lebanony method 
may work equally well without measuring miR-21 (Fig. 3 and 
Fig. S4 in Supplementary Digital Content, http://links.lww.
com/JTO/A750). This and the observation on the suitability 
of the method with only 0.2 ng RNA input (Fig. 2) is relevant 
because the amount of RNA from small biopsy material can 
FIGURE 4.  Expression of miR-205 and miR-375 in lung SCC 
and AC resectates. RT-PCR was used to quantify miR-205 rela-
tive to U6B and miR-21 (Lebanony score), and of miR-375 rela-
tive to U6B (miR-375 ΔCq
U6B) in 5 ng RNA for 49 AC (gray) and 
28 SCC (black) cases. Dotted lines indicate the median and SD 
values of miR-375 ΔCq
U6B and Lebanony scores of the AC cases 
with scores greater than 2.5. SCC, squamous cell carcinoma; 
AC, adenocarcinoma; RT-PCR, RT-PCR, reverse transcription-
polymerase chain reaction; SD, standard deviation.
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be limited. Finally, this study provides the molar equivalents 
of the cut-off values used for AC/SCC classification by the 
original and modified Lebanony methods. This should facili-
tate use of the methods’ principles for AC/SCC subtyping with 
platforms that do not use specific TaqMan RT-PCR assays to 
quantify microRNAs.
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